Alnylam Pharmaceuticals, Inc. $ALNY Stock: VIRGINIA RETIREMENT SYSTEMS ET Al Boosts Stake

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 655.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,060 shares of the biopharmaceutical company’s stock after purchasing an additional 26,080 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Alnylam Pharmaceuticals were worth $7,417,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ALNY. Parcion Private Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $308,000. China Universal Asset Management Co. Ltd. lifted its position in Alnylam Pharmaceuticals by 15.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 29,124 shares of the biopharmaceutical company’s stock valued at $7,400,000 after acquiring an additional 3,855 shares during the period. Pinnacle Wealth Planning Services Inc. lifted its position in Alnylam Pharmaceuticals by 60.4% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 446 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 168 shares during the period. North Dakota State Investment Board boosted its stake in Alnylam Pharmaceuticals by 8.3% during the third quarter. North Dakota State Investment Board now owns 4,082 shares of the biopharmaceutical company’s stock worth $1,007,000 after acquiring an additional 313 shares in the last quarter. Finally, Oppenheimer & Co. Inc. bought a new stake in Alnylam Pharmaceuticals during the third quarter worth about $234,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 30th. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a research note on Friday. Royal Bank Of Canada lowered their target price on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating for the company in a report on Friday. TD Cowen dropped their price target on Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Needham & Company LLC dropped their price target on Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating on the stock in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $317.95.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $165.00 on Friday. The business has a fifty day moving average price of $236.49 and a 200-day moving average price of $286.19. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The company has a market capitalization of $22.08 billion, a PE ratio of 8.57 and a beta of 0.28. Alnylam Pharmaceuticals, Inc. has a 1-year low of $163.30 and a 1-year high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the previous year, the business posted $2.90 EPS. Alnylam Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.58 EPS for the current fiscal year.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.